Wearable Injectors Market by Product Type(On-Body and Off-Body), Therapy (Immuno-oncology, Diabetes, Cardiovascular diseases), Technology(Spring-based, Motor Driven, Rotary Pump, Expanding Battery), Care Setting (Hospitals) - Global Forecast to 2026
[193 Pages Report] The global wearable injectors market is projected to reach USD 11.5 billion by 2026 from USD 7.2 billion in 2021, at a CAGR of 9.9% during the forecast period. Growth in this market is mainly driven by factors such as the shift of healthcare delivery toward homecare due to COVID-19, advantages of wearable injectors in the administration of various drugs, the rising prevalence of chronic diseases (such as cancer, diabetes, and CVD), favorable reimbursement scenario in major markets, and technological advancements in injector devices. However, the preference for alternative drug delivery modes, high costs, and a poor reimbursement structure in developing countries are expected to limit the adoption of wearable injectors to a certain extent.
To know about the assumptions considered for the study, Request for Free Sample Report
Covid-19 Impact on the wearable injectors Market
The COVID-19 pandemic is expected to have a positive impact on the wearable injectors market. In response to COVID-19, there has been a reorientation of medical priorities across healthcare institutions, with treatment for COVID-19 patients being the utmost priority. This has impacted the growth of the wearable injectors market. Wearable injectors represent a meaningful platform to bridge the gap between autoinjectors and in-clinic care.
Wearable injectors are expected to fill important gaps in healthcare infrastructure and connected health services. Currently, a rise in chronic ailments stemming from COVID-19 morbidity will partially fuel growth in the adoption of wearable injectors as patients with chronic pulmonary, cardiovascular, and neurological conditions begin to manage the long-term effects of the disease. Patients with chronic diseases are demanding a shift from clinic to at-home drug delivery to protect themselves from COVID-19 exposure in clinics.
Also, with the increased understanding that conditions like immune deficiency disorders result in not only vaccine resistance but also predispose patients to prolonged illness due to COVID-19, patients are exercising more caution. Infused therapies account for USD 35 billion in the specialty drugs market. It is estimated that shifting these treatments from hospitals or clinics to home care may confer 30–70% cost savings for both patients and healthcare payers. Wearable injector solutions are particularly well-suited for infusion therapies, as the pumps are designed to deliver large doses over minutes, and even hours; biologics and high viscosity drugs, including chemotherapy, monoclonal antibodies, and drugs targeted to auto-immune, blood, and genetic disorders, are commonly combined with wearable injector devices to support patient care at home and as an alternative to in-clinic care.
Wearable injectors Market Dynamics
Driver: Shift of healthcare delivery toward homecare due to COVID-19
The uncertainty caused by the COVID-19 pandemic has influenced the demand for different therapies and wearable drug delivery devices. To avoid the spread of the infection and protect high-risk patients from getting infected, healthcare systems across the globe undertook measures to postpone treatments for various diseases such as cancer. At the onset of the pandemic, the risks for patients receiving care increased. Also, hospitals, where a majority of patients receive treatments, became high-risk centers during the pandemic. In an effort to counter these challenges and provide effective care to patients suffering from various diseases, there has been a shift from hospital-based care to home-based care.
In the UK, NHS England rolled out a program permitting convenient, non-hospital-based treatments for cancer patients due to the COVID-19 pandemic. The adoption of wearable injectors for the delivery of oncology drugs and other maintenance therapies currently undergoing clinical trials has gained prominence during this pandemic.
As a result of the pandemic, there is an increased acceptance of telehealth and homecare. This has driven a shift in healthcare delivery from hospitals/clinics to home care settings. This is expected to create significant growth opportunities for market players in the coming years.
Opportunity: Increasing demand for biologics and mAbs
A growing focus on the use of biologics and mAbs to treat diseases such as rheumatoid arthritis, cardiovascular disease, and cancer will provide significant growth opportunities for wearable injectors, as these drugs need to be administered via the parenteral route (intravenous, subcutaneous, or intramuscular delivery). According to PhRMA (Pharmaceutical Research and Manufacturers of America), as many as 907 biologics were in development in 2013; the number of biologic drugs in development is continuing to increase exponentially, with more than 2,700 remedies in development as of mid-2017, triple the 907 in development in 2013. mAb-based biotherapies account for 50% of the top 100 drugs and are projected to maintain a dominant position in the pharmaceutical market.
Challenge: Unfavorable reimbursement structure in developing countries
A number of developing countries do not offer reimbursement for wearable injectors. For instance, in India, wearable insulin pumps are not reimbursed, and no specific guidelines regarding their use are given on prescription. In China, patients with Type 1 diabetes have to bear the entire cost of insulin pumps and supplies out-of-pocket. The lack of reimbursement directly affects access to and the adoption of wearable injectors and is thus expected to negatively impact the growth of the market in the coming years.
The on-body injectors holds the largest share in wearable injectors market by type, in the forecast period
The on-body accounted for the largest share in the forecast year. The large share of this segment can be attributed to the patients ease to deliver a precise amount of drug to the body over a controlled period of time.
The spring-based technology segment accounted for the largest share in the forecast period. The large share of this segment can be attributed to the rising demand for adhesive patches, as these devices are user-friendly and enable patients to accurately deliver the required drug subcutaneously.
The diabetes segment accounted for the largest share in the forecast period. The large share of this segment can be attributed to The high burden of diabetes across the globe, coupled with the growing availability of wearable injectors for the treatment of these diseases, is driving the growth of this market segment
The hospitals and clinics segment accounted for a larger market share during the forecast period. The large share of this segment can primarily be attributed to the rising preference for the self-administration of medication and the increasing need to curb healthcare costs. In addition, the growing demand for technologically developed drug delivery approaches, which lower the hospitalization rate and require minimal expertise, is expected to boost the growth of the home healthcare settings segment.
North America accounted for the largest share of the global wearable injectors market., by region in the forecast period.
North America accounted for the largest share of the global wearable injectors market. The large share of North America in this market is due to the rising prevalence of chronic and lifestyle-related diseases and the presence of advanced healthcare infrastructure in the region.
Key Market Players
Key players in the Wearable injectors market: Becton, Dickinson and Company(US), Ypsomed (Switzerland), Amgen (US), Subcuject (Denmark), Enable Injections (US), Medtronic plc (Ireland), Insulet Corporation (US), United Therapeutics Corp. (US), CeQur SA (Switzerland), Sensile Medical (Switzerland), SteadyMed Therapeutics (US), ATS Automation (Canada), West Pharmaceutical Services, Inc. (US), Unilife Corporation (UK), Tandem Diabetes Care (US), Valeritas (US), Bühler Motor (Switzerland), Sonceboz (Switzerland), Noble (US), Elcam Drug Delivery Devices (Israel), Bespak Europe Ltd. (UK), Stevanato Group (Italy), Sorrel Medical (Israel), Weibel CDS AG (Switzerland), and Neuma (US).
Scope of the report
|
Report Metric |
Details |
|
Market Size available for years |
2019-2026 |
|
Base Year Considered |
2020 |
|
Forecast period |
2021-2026 |
|
Forecast Unit |
Value (USD Billion) |
|
Segments covered |
Wearable injectors Market: |
|
Geographies covered |
|
|
Companies Covered |
Becton, Dickinson and Company(US), Ypsomed(Switzerland), Amgen(US), Subcuject(Denmark), Enable Injections(US), Medtronic Plc(Ireland), Insulet Corporation(US), United Therapeutics Corp (Us), CeQur SA(Switzerland), Sensile Medical(Switzerland), Steadymed Therapeutics (US), ATS Automation(Canada), West Pharmaceutical Services, Inc(US), Unilife Corporation(UK), Tandem Diabetes Care(US), Valeritas(US), Bühler Motor(Switzerland), Sonceboz(Switzerland), Noble(US), Elcam Drug Delivery Device(Israel), Bespak (UK), Stevanato Group(Italy), Sorrel Medical(Israel), Weibel CDS AG(Switzerland) and Neuma(US). |
The research report categorizes the market into the following segments:
Wearable Injectors Market, By Type
- On-body Injector
- Off-body Injector
Wearable Injectors Market, By Technology
- Spring Based
- Motor Based
- Rotary pump
- Expanding battery
- Other technology
Wearable Injectors Market, By Therapy
- Immuno-oncology
- Diabetes
- Cardiovascular disease
- Other disease
Wearable Injectors Market, By End User
- Hospitals and clinics
- Home healthcare setting
Wearable Injectors Market, by Region
- North America North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific (RoAPAC)
- Latin America
- Middle East & Africa
Recent Developments:
PRODUCT LAUNCHES
Month & Year |
COMPANY Name |
APPROACH |
Segment |
Product |
|
April 2021 |
Medtronic (Ireland) |
Product Launch |
Diabetes |
Infusion Set that can be worn up to seven days |
|
February 2021 |
United Therapeutics (US) |
Product Launch |
Cardiovascular |
Received FDA approval for its Remunity Disposable Subcutaneous Pump |
|
January 2021 |
Insulet Corporation (US) |
Product Launch |
Diabetes |
New Omnipod DASH Insulin Management System |
|
June 2020 |
Medtronic (Ireland) |
Product Launch |
Diabetes |
MiniMed 780G |
|
June 2018 |
Insulet Corporation (US) |
FDA Approval |
Diabetes |
Omnipod DASH Insulin Management System |
DEALS
Month & Year |
Deal Type |
Company 1 |
Company 2 |
Description |
|
April 2021 |
Acquisition |
Amgen (US) |
Five Prime Therapeutics (US) |
This acquisition—for USD 38.00 per share in cash—was focused on developing immuno-oncology and targeted cancer therapies. |
|
March 2021 |
Partnership |
Aptar and Noble International (US) |
Dne Pharma (Norway) |
Aptar Pharma’s Unidose Liquid System will be used by Dne Pharma as part of a broad patient onboarding and awareness program for Ventizolve. |
|
February 2021 |
Collaboration |
Subcuject (Denmark) |
Philips-Medisize (US) |
This collaboration was focused on the development, manufacturing, and commercialization of Subcuject WBI. |
|
September 2020 |
Collaboration |
Ypsomed |
SCHOTT and Lonza |
The three companies are developing a comprehensive solution for wearable patch injectors for the subcutaneous self-injection of large volumes of liquid formulations. |
|
May 2020 |
Partnership |
Ypsomed (Switzerland) |
Dexcom (US) |
This partnership was focused on the development of a hybrid closed-loop system. |
OTHER DEVELOPMENTS
|
MONTH & Year |
TYPE OF DEVELOPMENT |
COMPANY NAME |
DESCRIPTION |
|
September 2020 |
Expansion |
Insulet Corporation (US) |
The company expanded its presence in Sweden, Finland, Norway, and Denmark. |
|
March 2018 |
Expansion |
Ypsomed (Switzerland) |
Ypsomed established its first subsidiary in Canada. |
|
March 2018 |
Expansion |
Enable Injections (US) |
The company planned to employ an arcuately expandable elastomer bladder and injection cannula system. |
Frequently Asked Questions (FAQ):
Which are the top industry players in the global wearable injectors market?
The top market players in the global wearable injectors market include are Becton, Dickinson and Company(US), Ypsomed (Switzerland), Amgen (US), Subcuject (Denmark), Enable Injections, Inc(US), Medtronic plc (Ireland), Insulet Corporation (US), United Therapeutics Corp. (US), CeQur SA (Switzerland) and Sensile Medical (Switzerland).
Which are the segments that have been included in this report?
This report has the following main segments:
In the wearable injectors market:
- By Type
- By Technology
- By Therapy
- By End User
- By Region
Which geographical region is dominating in the wearable injectors market?
The global wearable injectors market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2020, the North American region dominated the global wearable injectors market. The prominence of the North American region in this market can be attributed to the rising prevalence of chronic and lifestyle-related diseases and the presence of advanced healthcare infrastructure in the region.
Which is the leading segment in the wearable injectors market, by type?
The on-body accounted for the largest share in the forecast year. The large share of this segment can be attributed to the patients ease to deliver a precise amount of drug to the body over a controlled period of time.
What is the current size of the global wearable injectors market?
The global wearable injectors market is projected to reach USD 11.5 billion by 2026 from USD 7.2 billion in 2021, at a CAGR of 9.9% during the forecast period. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 18)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 WEARABLE INJECTORS MARKET SEGMENTATION
FIGURE 2 WEARABLE INJECTORS MARKET, BY REGION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
TABLE 1 STANDARD CURRENCY CONVERSION RATES
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 23)
2.1 RESEARCH DATA
FIGURE 3 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 4 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (WEARABLE INJECTORS MARKET)
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: AMGEN INC.
FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: WEARABLE INJECTORS MARKET (2020)
FIGURE 10 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE WEARABLE INJECTORS MARKET (2021-2026)
FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 12 BOTTOM-UP APPROACH
FIGURE 13 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 14 DATA TRIANGULATION METHODOLOGY
2.4 MARKET RANKING ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY
2.6 RISK ASSESSMENT
2.7 COVID-19 HEALTH ASSESSMENT
2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE WEARABLE INJECTORS MARKET
FIGURE 15 WEARABLE INJECTORS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 16 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 17 WEARABLE INJECTORS MARKET, BY THERAPY, 2021 VS. 2026 (USD MILLION)
FIGURE 18 WEARABLE INJECTORS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 19 GEOGRAPHIC SNAPSHOT OF THE WEARABLE INJECTORS MARKET
3 EXECUTIVE SUMMARY (Page No. - 38)
4 PREMIUM INSIGHTS (Page No. - 43)
4.1 WEARABLE INJECTORS MARKET OVERVIEW
FIGURE 20 SHIFT OF HEALTHCARE DELIVERY TOWARD HOMECARE DUE TO COVID-19 IS DRIVING MARKET GROWTH
4.2 NORTH AMERICAN WEARABLE INJECTORS MARKET, BY COUNTRY AND THERAPY
FIGURE 21 DIABETES SEGMENT COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020
4.3 WEARABLE INJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 22 MARKET IN CHINA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
4.4 WEARABLE INJECTORS MARKET: REGIONAL MIX
FIGURE 23 NORTH AMERICA IS THE LARGEST MARKET FOR WEARABLE INJECTORS
5 MARKET OVERVIEW (Page No. - 47)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 24 WEARABLE INJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Shift of healthcare delivery toward homecare due to COVID-19
5.2.1.2 Advantages of wearable injectors in the administration of various drugs
5.2.1.3 Growing prevalence of chronic diseases
5.2.1.4 Favorable reimbursement scenario in major markets
5.2.1.5 Technological advancements and design development
5.2.2 RESTRAINTS
5.2.2.1 Preference for alternative drug delivery modes
5.2.2.2 High cost of wearable injectors
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing demand for biologics and mAbs
FIGURE 25 US: BIOLOGIC MEDICINES IN DEVELOPMENT, 2017
5.2.4 CHALLENGES
5.2.4.1 Unfavorable reimbursement structure in developing countries
6 INDUSTRY INSIGHTS (Page No. - 52)
6.1 TECHNOLOGY ANALYSIS
6.2 PRICING ANALYSIS
TABLE 2 AVERAGE SELLING PRICE: WEARABLE INJECTORS
6.3 VALUE CHAIN ANALYSIS
FIGURE 26 WEARABLE INJECTORS MARKET: VALUE CHAIN ANALYSIS
6.4 ECOSYSTEM MARKET MAP
FIGURE 27 WEARABLE INJECTORS MARKET: ECOSYSTEM MARKET MAP
6.5 SUPPLY CHAIN ANALYSIS
FIGURE 28 WEARABLE INJECTORS MARKET: SUPPLY CHAIN ANALYSIS
6.6 PORTER’S FIVE FORCES ANALYSIS
FIGURE 29 PORTER’S FIVE FORCES ANALYSIS (2020): WEARABLE INJECTORS MARKET
TABLE 3 WEARABLE INJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS
6.6.1 THREAT OF NEW ENTRANTS
6.6.1.1 Growth in the overall wearable injectors market
6.6.1.2 Growing consolidation
6.6.1.3 Poor financing environment
6.6.2 THREAT OF SUBSTITUTES
6.6.3 BARGAINING POWER OF SUPPLIERS
6.6.4 BARGAINING POWER OF BUYERS
6.6.5 INTENSITY OF COMPETITIVE RIVALRY
6.7 REGULATORY ANALYSIS
6.8 PATENT ANALYSIS
6.8.1 PATENT PUBLICATION TRENDS FOR WEARABLE INJECTORS
FIGURE 30 GLOBAL PATENT PUBLICATION TRENDS (2015–2020)
6.9 IMPACT OF COVID-19 ON THE WEARABLE INJECTORS MARKET
7 WEARABLE INJECTORS MARKET, BY TYPE (Page No. - 62)
7.1 INTRODUCTION
TABLE 4 WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
7.2 ON-BODY INJECTORS
7.2.1 ON-BODY INJECTORS SEGMENT DOMINATED THE MARKET IN 2020
TABLE 5 ON-BODY WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 OFF-BODY INJECTORS
7.3.1 OFF-BODY INJECTORS SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
TABLE 6 OFF-BODY WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8 WEARABLE INJECTORS MARKET, BY TECHNOLOGY (Page No. - 66)
8.1 INTRODUCTION
TABLE 7 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
8.2 SPRING-BASED TECHNOLOGY
8.2.1 SPRING-BASED TECHNOLOGY ENABLES THE DELIVERY OF DRUGS WITH HIGHER VOLUME AND VISCOSITY
TABLE 8 WEARABLE INJECTORS MARKET FOR SPRING-BASED TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 MOTOR-DRIVEN TECHNOLOGY
8.3.1 THESE DEVICES CAN GENERATE HIGH FORCE FOR SUBCUTANEOUS INJECTIONS OF HIGH-VISCOSITY LIQUIDS
TABLE 9 WEARABLE INJECTORS MARKET FOR MOTOR-DRIVEN TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 ROTARY PUMP TECHNOLOGY
8.4.1 THESE DEVICES SHOW HIGH PRECISION AND THE POSSIBILITY TO NOT ALTER THE FLUID PROPERTIES
TABLE 10 WEARABLE INJECTORS MARKET FOR ROTARY PUMP TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 EXPANDING BATTERY TECHNOLOGY
8.5.1 EXPANDING BATTERY TECHNOLOGY SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
TABLE 11 WEARABLE INJECTORS MARKET FOR EXPANDING BATTERY TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
8.6 OTHER TECHNOLOGIES
TABLE 12 WEARABLE INJECTORS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2019–2026 (USD MILLION)
9 WEARABLE INJECTORS MARKET, BY THERAPY (Page No. - 73)
9.1 INTRODUCTION
TABLE 13 WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
9.2 DIABETES
9.2.1 HIGH PREVALENCE OF DIABETES ACROSS THE GLOBE TO DRIVE THE GROWTH OF THIS MARKET SEGMENT
TABLE 14 INSULIN DEVICES AVAILABLE FOR DIABETES PATIENTS
TABLE 15 WEARABLE INJECTORS MARKET FOR DIABETES, BY COUNTRY, 2019–2026 (USD MILLION)
9.3 IMMUNO-ONCOLOGY
9.3.1 IMMUNO-ONCOLOGY SEGMENT TO WITNESS NEGATIVE GROWTH DURING THE FORECAST PERIOD
TABLE 16 WEARABLE INJECTORS MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
9.4 CARDIOVASCULAR DISEASES
9.4.1 CARDIOVASCULAR DISEASES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
TABLE 17 WEARABLE INJECTORS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
9.5 OTHER THERAPIES
TABLE 18 WEARABLE INJECTORS MARKET FOR OTHER THERAPIES, BY COUNTRY, 2019–2026 (USD MILLION)
10 WEARABLE INJECTORS MARKET, BY END USER (Page No. - 80)
10.1 INTRODUCTION
TABLE 19 WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2 HOSPITALS AND CLINICS
10.2.1 HOSPITALS AND CLINICS ARE THE LARGEST END USERS OF WEARABLE INJECTORS
TABLE 20 WEARABLE INJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2019–2026 (USD MILLION)
10.3 HOME HEALTHCARE SETTINGS
10.3.1 HOME HEALTHCARE SETTINGS SEGMENT TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD
TABLE 21 WEARABLE INJECTORS MARKET FOR HOME HEALTHCARE SETTINGS, BY COUNTRY, 2019–2026 (USD MILLION)
11 WEARABLE INJECTORS MARKET, BY REGION (Page No. - 84)
11.1 INTRODUCTION
FIGURE 31 WEARABLE INJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 22 WEARABLE INJECTORS MARKET, BY REGION, 2019–2026 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 32 NORTH AMERICA: WEARABLE INJECTORS MARKET SNAPSHOT
TABLE 23 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY COUNTRY,2019–2026 (USD MILLION)
TABLE 24 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 25 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 26 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 27 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
11.2.1 US
11.2.1.1 Growing IV infusion expenditure is a key factor driving the US market.
TABLE 28 US: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 29 US: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 30 US: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 31 US: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Rising prevalence of chronic diseases in Canada to drive the demand for drugs that can be self-administered
TABLE 32 CANADA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 33 CANADA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 34 CANADA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 35 CANADA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3 EUROPE
FIGURE 33 EUROPE: WEARABLE INJECTORS MARKET SNAPSHOT
TABLE 36 EUROPE: WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 37 EUROPE: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 38 EUROPE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 39 EUROPE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 40 EUROPE: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Availability of government support for drug development and approval to drive growth in the German wearable injectors market
TABLE 41 GERMANY: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 42 GERMANY: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 43 GERMANY: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 44 GERMANY: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3.2 UK
11.3.2.1 Government focus on biosimilar innovation to drive the market growth
TABLE 45 UK: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 46 UK: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 47 UK: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 48 UK: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 100% coverage for diabetes by SHI to drive market growth in France
TABLE 49 FRANCE: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 50 FRANCE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 51 FRANCE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 52 FRANCE: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3.4 REST OF EUROPE
TABLE 53 ROE: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 54 ROE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 55 ROE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 56 ROE: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
11.4 ASIA PACIFIC
TABLE 57 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 58 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 59 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 60 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 61 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
11.4.1 JAPAN
11.4.1.1 Large number of patients suffering from diabetes, CVD, and other chronic conditions to drive market growth in Japan
TABLE 62 JAPAN: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 63 JAPAN: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 64 JAPAN: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 65 JAPAN: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Large diabetic population to drive market growth in China
TABLE 66 CHINA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 67 CHINA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 68 CHINA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 69 CHINA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Large diabetic population to drive the market for wearable injectors in India
TABLE 70 INDIA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 71 INDIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 72 INDIA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 73 INDIA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 74 ROAPAC: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 75 ROAPAC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 76 ROAPAC: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 77 ROAPAC: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 INCREASING PREVALENCE OF DIABETES AND OTHER CHRONIC CONDITIONS TO DRIVE THE MARKET IN LATIN AMERICA
TABLE 78 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 79 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 80 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 81 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 DEMAND FOR WEARABLE INJECTORS IN THE MANAGEMENT OF DIABETES AND CVD IS EXPECTED TO INCREASE IN THE MIDDLE EAST AND AFRICA
TABLE 82 CONFERENCES IN THE MIDDLE EAST AND AFRICA (2016–2018)
TABLE 83 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 84 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 85 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION)
TABLE 86 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 125)
12.1 INTRODUCTION
FIGURE 34 KEY MARKET DEVELOPMENTS (JANUARY 2018 TO JULY 2021)
12.2 REVENUE ANALYSIS OF KEY MARKET PLAYERS
FIGURE 35 REVENUE ANALYSIS OF THE KEY PLAYERS OPERATING IN THE WEARABLE INJECTORS MARKET
12.3 MARKET SHARE ANALYSIS
FIGURE 36 WEARABLE INJECTORS MARKET SHARE, BY KEY PLAYER, 2020
12.4 COMPETITIVE SCENARIO
12.4.1 PRODUCT LAUNCHES
TABLE 87 WEARABLE INJECTORS MARKET: PRODUCT LAUNCHES (JANUARY 2018 TO JULY 2021)
12.4.2 DEALS
TABLE 88 WEARABLE INJECTORS MARKET: DEALS (JANUARY 2018 TO JULY 2021)
12.4.3 OTHER DEVELOPMENTS
TABLE 89 WEARABLE INJECTORS MARKET: OTHER DEVELOPMENTS (JANUARY 2018 TO JULY 2021)
12.5 COMPETITIVE BENCHMARKING
12.6 COMPANY EVALUATION MATRIX
12.6.1 STARS
12.6.2 EMERGING LEADERS
12.6.3 PERVASIVE PLAYERS
12.6.4 EMERGING COMPANIES
FIGURE 37 WEARABLE INJECTORS MARKET: GLOBAL COMPANY EVALUATION MATRIX
12.7 COMPETITIVE LEADERSHIP MAPPING (SMES/START-UPS)
12.7.1 PROGRESSIVE COMPANIES
12.7.2 STARTING BLOCKS
12.7.3 RESPONSIVE COMPANIES
12.7.4 DYNAMIC COMPANIES
FIGURE 38 WEARABLE INJECTORS MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS
13 COMPANY PROFILES (Page No. - 140)
13.1 KEY PLAYERS
(Business Overview, Products, Key Insights, Recent Developments, MnM View)*
13.1.1 AMGEN INC.
TABLE 90 AMGEN INC.: BUSINESS OVERVIEW
FIGURE 39 AMGEN INC.: COMPANY SNAPSHOT (2020)
13.1.2 MEDTRONIC PLC
TABLE 91 MEDTRONIC PLC: BUSINESS OVERVIEW
FIGURE 40 MEDTRONIC PLC: COMPANY SNAPSHOT (2020)
13.1.3 INSULET CORPORATION
TABLE 92 INSULET CORPORATION: BUSINESS OVERVIEW
FIGURE 41 INSULET CORPORATION: COMPANY SNAPSHOT (2020)
13.1.4 BECTON, DICKINSON AND COMPANY
TABLE 93 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
13.1.5 YPSOMED
TABLE 94 YPSOMED: BUSINESS OVERVIEW
FIGURE 43 YPSOMED: COMPANY SNAPSHOT (2020)
13.1.6 UNITED THERAPEUTICS CORPORATION
TABLE 95 UNITED THERAPEUTICS CORPORATION: BUSINESS OVERVIEW
FIGURE 44 UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT (2020)
13.1.7 SUBCUJECT
TABLE 96 SUBCUJECT: BUSINESS OVERVIEW
13.1.8 ENABLE INJECTIONS
TABLE 97 ENABLE INJECTIONS: BUSINESS OVERVIEW
13.1.9 CEQUR SA
TABLE 98 CEQUR SA: BUSINESS OVERVIEW
13.1.10 SENSILE MEDICAL (A PART OF GERRESHEIMER)
TABLE 99 SENSILE MEDICAL: BUSINESS OVERVIEW
13.2 OTHER PLAYERS
13.2.1 STEADYMED THERAPEUTICS
TABLE 100 STEADYMED THERAPEUTICS: BUSINESS OVERVIEW
13.2.2 ATS AUTOMATION
TABLE 101 ATS AUTOMATION: BUSINESS OVERVIEW
FIGURE 45 ATS AUTOMATION: COMPANY SNAPSHOT (2020)
13.2.3 WEST PHARMACEUTICAL SERVICES, INC.
TABLE 102 WEST PHARMACEUTICAL SERVICES, INC.: BUSINESS OVERVIEW
FIGURE 46 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2020)
13.2.4 UNILIFE CORPORATION
TABLE 103 UNILIFE CORPORATION: BUSINESS OVERVIEW
13.2.5 TANDEM DIABETES CARE
TABLE 104 TANDEM DIABETES CARE: BUSINESS OVERVIEW
FIGURE 47 TANDEM DIABETES CARE: COMPANY SNAPSHOT (2020)
13.2.6 VALERITAS, INC.
TABLE 105 VALERITAS, INC.: BUSINESS OVERVIEW
FIGURE 48 VALERITAS, INC.: COMPANY SNAPSHOT (2020)
13.2.7 BÜHLER MOTOR GMBH
TABLE 106 BÜHLER MOTOR GMBH: BUSINESS OVERVIEW
FIGURE 49 BÜHLER MOTOR GMBH: COMPANY SNAPSHOT (2020)
13.2.8 SONCEBOZ
TABLE 107 SONCEBOZ: BUSINESS OVERVIEW
13.2.9 NOBLE INTERNATIONAL LLC (AN APTAR PHARMA COMPANY)
TABLE 108 NOBLE INTERNATIONAL LLC: BUSINESS OVERVIEW
FIGURE 50 NOBLE INTERNATIONAL LLC: COMPANY SNAPSHOT (2020)
13.2.10 ELCAM DRUG DELIVERY DEVICES (E3D)
TABLE 109 ELCAM DRUG DELIVERY DEVICES: BUSINESS OVERVIEW
13.2.11 BESPAK EUROPE LTD.
TABLE 110 BESPAK EUROPE LTD.: BUSINESS OVERVIEW
FIGURE 51 BESPAK EUROPE LTD.: COMPANY SNAPSHOT (2020)
13.2.12 STEVANATO GROUP
TABLE 111 STEVANATO GROUP: BUSINESS OVERVIEW
13.2.13 SORREL MEDICAL
TABLE 112 SORREL MEDICAL: BUSINESS OVERVIEW
13.2.14 WEIBEL CDS
TABLE 113 WEIBEL CDS: BUSINESS OVERVIEW
13.2.15 NEUMA LLC
TABLE 114 NEUMA: BUSINESS OVERVIEW
*Details on Business Overview, Products, Key Insights, Recent Developments, MnM View might not be captured in case of unlisted companies.
14 APPENDIX (Page No. - 187)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Business, Factiva, and D&B Hoovers), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the wearable injectors market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The wearable injectors market comprises several stakeholders such as wearable injector manufacturers and distributors and regulatory organizations. The demand side of this market is characterized by hospitals & clinics, and home healthcare setting.
Various primary sources from both, the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.
Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.
A breakdown of the primary respondents for wearable injectors market is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by type, by technology, by therapy, by end user, and by region).
Data Triangulation
After arriving at the market size, the total wearable injectors market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation, and market breakdown procedures were employed, wherever applicable.
Objectives of the Study
- To define, describe, analyze, and forecast the size of the wearable injectors market on the basis of type, technology, therapy, end user and region.
- To provide detailed information on the major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges)
- To strategically analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To forecast the size of the market segments with respect to North America, Europe, Asia Pacific, latin America and Middle East and Africa.
- To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies.
- To track and analyze competitive developments such as product launches, partnerships, acquisitions and other developments in the market.
- To benchmark players within the wearable injectors market using the Competitive Leadership Mapping framework which analyzes market players on various parameters within the broad categories of business and product strategy.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players
Geographic Analysis
- Further breakdown of the Rest of Asia Pacific wearable injectors market into South Korea, New Zealand, and other countries.
Get in-depth analysis of the COVID-19 impact on the Wearable Injectors Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Wearable Injectors Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Wearable Injectors Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Wearable Injectors Market